David Koppein
Payments from drug & device makers
Across 90 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$535
- Pfizer$100
- Otsuka America Pharmaceutical, Inc.$93
- AstraZeneca$86
- GSK$75
- Bayer$63
- plus $478 from 15 others
What the payments were for
- Food & beverage$1,430100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $535 |
| Pfizer | 7 | $100 |
| Otsuka America Pharmaceutical, Inc. | 4 | $93 |
| AstraZeneca | 5 | $86 |
| GSK | 5 | $75 |
| Bayer | 4 | $63 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $58 |
| Lilly USA, LLC | 4 | $57 |
| Axsome Therapeutics, Inc. | 3 | $52 |
| Vertex | 3 | $50 |
| Abbott | 3 | $46 |
| Phathom Pharmaceuticals, Inc. | 2 | $42 |
| Medtronic | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Verona Pharma, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Amgen | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Novartis | 1 | $13 |
How this compares
$1,430 in reported general payments places this provider in the 75th percentile of 2,103 family providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 124 | $81,301 |
| MounjaroTirzepatide | 52 | $52,832 |
| JardianceEmpagliflozin | 40 | $37,278 |
| EliquisApixaban | 46 | $32,637 |
| TrulicityDulaglutide | 23 | $29,706 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 43 | $28,668 |
| OzempicSemaglutide | 20 | $18,709 |
| LinzessLinaclotide | 21 | $14,318 |
| MyrbetriqMirabegron | 22 | $12,958 |
| JanuviaSitagliptin Phosphate | 15 | $8,492 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $8,249 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 162 | $3,736 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,768 |
| DilantinPhenytoin Sodium Extended | 11 | $1,557 |
| Novolin R FlexpenInsulin Regular, Human | 11 | $1,511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $57 | $82,53775 claims |
| GSKTrelegy Ellipta | $75 | $81,301124 claims |
| PfizerEliquis, Dilantin | $100 | $34,19557 claims |
| AbbVieLinzess | $535 | $14,31821 claims |
| Astellas Pharma US IncMyrbetriq | $21 | $12,95822 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $86 | $11,01722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,103 family providers in Arkansas.
Other family in Mena
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
- Michael StirlingLittle Rock$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.